COVID-19: Haun, B.K., Lai, C.Y., Williams, C.A., Wong, T.A.S., Lieberman, M.M., Pessaint, L., Andersen, H., Lehrer, A.T. CoVaccine HT™ Adjuvant Potentiates Robust Immune Responses to Recombinant SARS-CoV-2 Spike S1 Immunization. 2020.
In this interview, Dr. Christopher J. Schaber, President and CEO, discusses the Company with The Wall Street Analyzer.
Journal of Biotechnology – Dusquetide: A Novel Innate Defense Regulator Demonstrating a Significant and Consistent Reduction in the Duration of Oral Mucositis in Preclinical Data and a Randomized, Placebo-Controlled Phase 2a Clinical Study
The publication of positive clinical results consistent with preclinical data
Journal of Biotechnology – A novel approach for emerging and antibiotic resistant infections: Innate defense regulators as an agnostic therapy
The publication of data demonstrating the mechanism and broad-spectrum activity of dusquetide in preclinical bacterial infection models